El cannabidiol y sus indicaciones en psiquiatría
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
Esta revisión abarca la historia, el origen, la síntesis biológica del cannabidiol (CBD), su interacción con el sistema de cannabinoides endógenos, las presentaciones para uso clínico, su farmacocinética, tolerabilidad y la evidencia actual de los usos en psiquiatría. Además del origen de su nombre y las precisiones de la taxonomía botánica de la cannabis, es de interés conocer a partir de estudios de polen fósil la cronología y ruta que siguió ancestralmente hasta la llegada a Europa y cómo allí se inició su estudio con la idea de introducirla en la farmacopea del momento y como modelo de estudio de trastornos cerebrales como las psicosis. Jacques Joseph Moreau de Tours (1804-1884), psiquiatra francés, la usó en forma de hachís y propició el consumo experimental por intelectuales de la época. Basado en la presunción de que intelectuales e individuos con una educación eran sujetos de estudio que podían proveer relatos más detallados y floridos de las experiencias vividas bajo sus efectos, Moreau de Tours concibió por primera vez que los efectos de la cannabis eran un paradigma experimental para el estudio de las psicosis. Luego experimentó su uso terapéutico con resultados negativos. En el caso del CBD, extraído de la cannabis, la psiquiatría contemporánea podría vislumbrar resultados más promisorios a través de la investigación clínica en diferentes indicaciones.
Citas
Fuchs L. The great herbal of leonhart fuchs: De Historia Stirpium Comentarii insignes, 1542 (Notable Commentaries on the History of Plants). Stanford (California): Stanford University Press; 1999.
Small E. Evolution and classification of cannabis sativa (Marijuana, Hemp) in Relation to Human Utilization. Bot Rev. 2015;81:189.
McPartland JM, Guy GW. Cannabis may have evolved in the northeastern Tibetan Plateau, based on an interdisciplinary study of genetics, fossil pollen and ecology. En: Proceedings of the 26th Annual Symposium on the Cannabinoids. International Cannabinoid Research Society: Research Triangle Park. 2016. p. 61.
O’Shaughnessy WB. On the preparations of the Indian Hemp, or Gunjah: Cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov Med J Retrosp Med Sci 1843;5:363-9.
Moreau JJ. La Psychologie morbide dans ses rapport avec la philosophie de l’histoire ou l’influence des neuropathies sur le dynamisme intellectual. París: Masson, 1859.
Kim ES, Mahlberg PG. Immunochemical localization of tetrahydrocannabinol (THC) in cryofixed glandular trichomes of cannabis (Cannabaceae). Am J Bot 1987;84:336-42.
ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences 2005;78:539-48.
Hanus Lo, Meyer SM, Muñoz E, Taglialatela-Scafatti O, Appendino G. Phytocannabinoids: a unified critical inventory. Natural Product Reports 2016;1357-92.
Russo E. Beyond cannabis: plants and the endocannabinoid system. Trends in Pharmacological Sciences 2016;37:594-605.
McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. Gene 2006;370:64-74.
Degenhart F, Stehle F, Kayser O. The biosynthesis of cannabinoids. En: Handbook of cannabis and related pathologies. 1.ª ed. Academic Press; 2017. Elsevier Inc. 13-23.
Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-47.
Marco EM, García Gutiérrez MS, Bermúdez-Silva FJ, Moreira FA, Guimarães F, Manzanares J, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci 2011;5:63.
Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963;19:2073-78.
Lafaye G, Karila L, Blecha L. Cannabis, cannabinoids and health. Dialogues Clin Neurosc. 2017;19:309-17.
Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 2015;12:692-8.
Lu D, Potter DE. Cannabinoids and the cannabinoid receptors: an Overview. En: Handbook of cannabis and related pathologies. Elsevier; 2017.
Onaivi ES, Ishiguro H, Gong JP. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006;1074:514-36.
Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007;13:127-37.
Campos AC, Araújo-Moreira F, Villela-Gomes F, Aparecidad del Bel E, Silverira- Gimaraes F. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc 2012;367:3364-78.
Laprairie RB, Bagher A, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015;172:4790-805.
United Nations Office on Drug and Crime. Convención Única de 1961 sobre Estupefacientes [Internet] [Consultado 3 de agosto de 2019]. Disponible en: https://www.unodc.org/pgl/convention_1961es.pgl.
United Nations Office on Drug and Crime. UNDOC. Convenio sobre Sustancias Sicotrópicas [internet] [Consultado 3 de agosto de 2019] Disponible en: https://www.undoc.org/pgl/convention_1971_es
Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G. Quality traits of “cannabidiol oils”: cannabinoids content, terpene fingerprint and oxidization stability of european comercially available preparations. Molecules 2018;23:1-5.
Senado de la República de Colombia. Ley 1787 [Internet] [Consultado el 3 de agosto de 2019] Disponible en: http://www.secretariasenado.gov.co/senado/basedoc/ley_1787_2016.html.
Ministerio de Salud de la República de Colombia. Decreto 613 de 2017. [Internet] Consultado el 3 de agosto de 2019] Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/decreto-613-de-2017.pdf.
Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardó FP, Pichini S. Evaluation of cannabinoids concentration a stability in standardized preparations of cannabis tea and cannabis oil by ultrahigh-performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55:1555-63.
Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA. Medicinal cannabis: principal cannabinoids concentration and their stability evaluated by a high-performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal 2016;128:201-9.
Giese MW, Lewis MA, Giese L, Smith KM. Development and validation of a reliable and robust method for the analysis of cannabinoids and terpenes in cannabis. J AOAC Int 2015:98:1503-22.
Bettiol A, Lombardi N, Crescioli G, Maggini V, Gallo E. Galenic preparations of therapeutic cannabis sativa differ in cannabinoids concentration: a quantitative analysis of variability and possible clinical implications. Frontiers Pharmacol 2019;9:1543.
Pellati F, Brighenti V, Sperlea J, Marchetti L, Bertelli D. New methods for the comprehensive analysis of bioactive compounds in Cannabis sativa L. (hemp). 2018;23:2639.
Booth JK, Bohlmann J. Terpenes in Cannabis Sativa: from plant genome to humans. Plant Science 2019;284:67-72.
Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharm 2011;163:1344-64.
Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol 2019;1-13.
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebocontrolled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2008;32:1053-67.
Brown J, Winterstein A. Potential adverse drug events and drug drug interactions with medical and consumer cannabidiol use. J Clin Med 2019;8:989.
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage effect: inactive
endogenous fatty acid glycerol cannabinoid activity. Eur J Pharmacol 1998;353:23-31.
Abuhasira R, Bar-Lev Schleider L, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficay of medical cannabis in the elderly. European J Intern Med 2018;49:44-50.
Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. 2.ª ed. Nueva York: Guilford; 2002.
Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2016;41:80-122.
White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacology 2019;59:923-34.
Zuardi AW, Suirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by THC in normal subjects. Psychopharmacology (Berl) 1982;76:245-50.
De Souza JA, Zuardi W, Garrido E. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004;29:417-26.
Lee JLC, Bertoglio LJ, Guimaraes FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. British J Pharmacol 2017;174:3242-56.
Bergamaschi M. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment: naïve social phobia patients. Neuropsychopharmacology 2011;36:1219-26.
Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Fr Psychol 2019;10:2466.
Elms L, Shannon S, Hughes S. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Alternative and Complimentary Med 2019;25:392-7.
Shannon S, Opila-Lehman J. Effectiveness of cannabidiol for pediatric anxiety an insomnia as part of a posttraumatic stress disorder: a case report. Perm J Fall 2016;20:16.
Van der Flier FE, Kwee CMB, Cath DC, Batelaan NM, Groenink L. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. BMC Psychiatry 2019;19:69.
Leweke FM, Piomelli D, Pahlisch F. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
McGuire P, Robson P, Cubala WJ. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018;175:225-31.
Makiol Ch, Kluge M. Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol. Aust N Z J Psychiatry 2019;53:262-5.
Barchel D, Stolar O, De Haan T, Ziv-Baran T, Saban. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-mobidities. Frontiers Pharmacol 2019;9:1521.
Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 2019;9:200.
Parsaik AK, Mascarenhas SS, Khosh-Chashm D. Mortality associated with anxiolytic and hypnotic drugs: a systematic review and meta-analysis. Aust N Z J Psychiatry 2015;50:520-33.
Purcell Ch, Davis A, Moolman N. Reduction of benzodiacepine use in patients prescribed medical cannabis. Cannabis Cannabinoid Res 2019;0:1-5.
Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 2005;81:300-18.
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004;161:1967-77.
Yücel M, Lorenzetti V, Suo C. Hippocampal harms, protection, and recovery following regular cannabis use. Transl Psychiatry 2016;6:e710.
Vann RE, Gamage TF, Warner JA. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of delta (9)-tetrahydrocannabinol. Drug Alcohol Depend 2008;94:191-8.
Englund A, Morrison PD, Nottage J. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal: dependent memory impairment. J Psychopharmacol 2013;27:19-27.
Crippa JA, Hallak, JE, Machado-de-Sousa JP, Queiroz RH. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 2013;38:162-4.
Scott S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med 2015;14:31-5.
Solowij N, Broyd S, Beale C, Prick JA. Therapeutic effects of prolongued cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 2018;3:21-34.
Hurd Y, Spriggs S, Alishayev J, Winkel G, Gurgov K. Cannabidiol for the reduction of cue-induced craving an anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 2019;176:911-22.
Linares IMP, Guimaraes FS, Eckeli A. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol 2018;9:315.
Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA. Cannabidiol can improve complex sleep-related behaviors associated with rapid eye movement sleep behavior disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther 2014;39:564-6.
Megelin T, Ghorayeb I. Cannabis for restless legs syndrome: a report of six patients. Sleep Medicine 2017;36:182-3.
Zuardi AW, Guimaraes FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone, and cortisol in human volunteers. Braz J Med Biol Res 1993;26:213-7.